Season 2 (2021-2030)

Immunology - Discovery (29)

Modality Indication Targets Stage Company Project No. Detail
1 Development of an sFasL-targeted antibody therapy for treating arthritis that is non-responsive or resistant to TNFα inhibitors
Antibody Rheumatoid Arthritis sFas L Hit Seoul National University RS-2023-00259272
2 Development of Hit/Lead compound using PKCη inhibitory drugs for treating multiple sclerosis
Small Molecules Multiple Sclerosis PKCη Hit Hanyang University RS-2023-00217324
3 Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation
Small Molecules Psoriasis Cannabinoid 1 receptor Hit Ajou University RS-2023-00217308
4 Development of STAT6 blocking therapeutic drug in systemic sclerosis with targeting profibrotic T cells and fibroblasts
Small Molecules Systemic Sclerosis STAT6 Hit The catholic university, medical college, LaTIM (Lab of Translational ImmunoMedicine) RS-2023-00217274
5 Identification a lead small-molecule drug to treat osteoarthritis through a cartilage regeneration mechanism
Small Molecules Osteoarthritis OSCAR Hit KaiPharm Co., Ltd. RS-2022-00167006
6 Therapeutic exosome development in Inflammatory Bowel Disease (IBD)
 with CARD9/TRIM62 Protein-Protein Interaction (PPI) inhibition activity
Others Inflammatory Bowel Disease CARD9, TRIM62 Hit ILIAS Biologics Inc. HN22C0582
7 Generation of hit/lead compounds to treat multiple sclerosis by targeting formyl peptide receptor
Peptide Multiple Sclerosis FPR Hit Sungkyunkwan University HN22C0255
8 Development of anti-fibrosis therapeutics for systemic sclerosis using SOS1- RAS interaction-specific blockade
Small Molecules Systemic Sclerosis SOS1/RAS Hit Kyungpook National University HN21C0307
9 Discovery study of CR-E1 targeting psoriasis lead compounds by regulating Th17 mechanism
Small Molecules Psoriasis CR-E1 Hit Curogen Technology HN21C0250
10 Development of SCED-based lead compounds for atopic dermatitis
Small Molecules Atopic dermatitis EGR1 Hit Konkuk University HN21C0984
11 Lead selection of allergen non.binding hybrid immunoglobulin E for the treatment of allergic severe asthma
Antibody Asthma FcεRIα Lead FatiAbGen Co., Ltd. RS-2023-00284138
12 Discovery of Selective IRAK4 Degrader based on Protac Technology
Small Molecules Systemic Lupus Erythematosus IRAK4 Lead College of Pharmacy, Gachon University RS-2023-00218618
13 Evaluation of drug efficacy and discovery of pharmacodynamics biomarkers of a new anti-CD40 antibody lead compound (PB101) for the treatment of Pemphigus, a rare intractable skin disease
Antibody Pemphigus CD40 Lead PB Immune Therapeutics RS-2022-00165917
14 Discovery of Leads as LRRK2 inhibitors for the treat of Crohn’s disease
Small Molecules Crohn's disease LRRK2 Lead Chung Ang University HN22C0690
15 Development of innovative monoclonal antibody drug targeting dimeric TCTP/HRF for treatment of chronic inflammatory diseases
Antibody Chronic Inflammatory diseases TCTP/HRF Lead Ewha Women's University HN22C0533
16 Discovery of Lead for a First-in-Class Drug Treating Inflammatory Bowel Disease (IBD)
Small Molecules Ulcerative colitis, Crohn's disease PIN1 Lead PimedBio HN22C0056
17 Lead selection and optimization of therapeutic anti- CD40 antibody for the treatment of multiple sclerosis
Antibody Multiple Sclerosis CD40 Lead PB immune therapeutics HN21C1359
18 Discovery of lead small molecules to control NLRP3 inflammasome
Small Molecules Psoriasis, Inflammatory disease NLRP3 Lead Ajou University HN21C1058
19 Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation
Others Psoriasis, Contact dermatitis Hyaluronic acid Lead Ajou University HN21C0958
20 Development of TYK2 pseudokinase domain selective inhibitor for autoimmune treatment
Small Molecules Psoriasis, Rheumatoid Arthritis Tyk2 Lead CrystalGenomic Inc. HN21C0189
21 Development of small-molecule asthma drug that inhibits the binding of IL-33 to its receptor
Small Molecules Asthma IL-33 Lead AZCURIS HN21C0187
22 Developing the drug candidates for psoriasis treatment using small molecule with IRAK.1/4 inhibition
Small Molecules Psoriasis IRAK1/4 Candidate Dongwha Pharm Co.,Ltd. RS-2023-00284094
23 Development of a novel RIPK1 inhibitor for autoimmune disease(BSC.1300)
Small Molecules Autoimmune diseases RIPK1 Candidate BiSiChem RS-2023-00259271
24 Development of a therapeutic agent for ulcerative colitis based on the regeneration mechanism of intestinal mucosa using an AIbased drug development platform
Small Molecules Ulcerative colitis 15.PGDH Candidate Innovo Therapeutics, Inc. RS-2023-00258490
25 Candidate selection for development of an immunosuppressive monoclonal antibody against allergic disease
Antibody Atopic dermatitis CD200R1 Candidate AIMEDBIO Inc. RS-2023-00218545
26 Novel antibody candidate for rheumatoid arthritis
Antibody Rheumatoid Arthritis WARS1 Candidate MirimGene RS-2022-00166575
27 Candidate Selection of IL-2v-SAFA for the treatment of rare autoimmune disease
Recombinant Protein Systemic Lupus Erythematosus, IBD IL-2 Candidate AprilBio RS-2022-00165592
28 Discovery of non-clinical candidates of new PKM2 activator that cure inflammation and fibrosis at the same time through cell metabolism modulation
Small Molecules Rheumatoid arthritis, IBD PKM2 Candidate Lmito Therapeutics HN21C0943
29 The generation of candidate for atopic dermatitis via selective STAT3 inhibition
Small Molecules Atopic dermatitis STAT3 Candidate C&C Research Laboratories HN21C0543
BACK